Abstract
Janus kinase-3 (JAK3), a tyrosine kinase, is expressed in a variety of tissues, including the brain and is involved in the signaling of cytokine receptors. JAK3 participates in numerous functions, such as cell survival and proliferation, neuroprotection, apoptosis and the cellular response to hypoxia and ischemia-reperfusion. This kinase further contributes to the signaling of hematopoietic cell cytokine receptors, activation of dendritic cells, maturation, and immune suppression as well as to cell volume regulation. Recently, JAK3 has been demonstrated to be an important regulator of transport processes across the plasma membrane. Either directly or indirectly JAK3 affects the expression of transport proteins, including various ion channels, a number of cellular carriers and the Na+/K+ pump. More specifically, JAK3 is involved in the regulation of various potassium, sodium, and chloride ion channels, a wide variety of Na+-coupled cellular carriers including the high-affinity Na+ coupled glucose transporter SGLT1, the excitatory amino acid transporters EAAT1, EAAT2, EAAT3 and EAAT4, the peptide transporters PepT1 and PepT2, CreaT1 and theNa+/K+-ATPase. Via these transporters this kinase plays a role in various physiological and pathophysiological processes. Additional research is needed to investigate the effects of JAK3 on other cellular transporters and the underlying mechanisms.
Keywords: JAK3, JAK-STAT, cellular transport, ion channels, membrane carriers, Na+/K+-ATPase.
Current Medicinal Chemistry
Title:Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Volume: 24 Issue: 21
Author(s): Mentor Sopjani*, Shpëtim Thaçi, Berat Krasniqi, Miranda Selmonaj, Mark Rinnerthaler and Miribane Dërmaku-Sopjani*
Affiliation:
- Faculty of Medicine of the University of Prishtina, Str. Bulevardi i Dëshmorëve, p.n. 10 000, Prishtina,Kosova
- Department of Chemistry, Faculty of Natural Sciences and Mathematics, University of Prishtina. Str. Mother Teresa, p.n. 10 000, Prishtina,Kosova
Keywords: JAK3, JAK-STAT, cellular transport, ion channels, membrane carriers, Na+/K+-ATPase.
Abstract: Janus kinase-3 (JAK3), a tyrosine kinase, is expressed in a variety of tissues, including the brain and is involved in the signaling of cytokine receptors. JAK3 participates in numerous functions, such as cell survival and proliferation, neuroprotection, apoptosis and the cellular response to hypoxia and ischemia-reperfusion. This kinase further contributes to the signaling of hematopoietic cell cytokine receptors, activation of dendritic cells, maturation, and immune suppression as well as to cell volume regulation. Recently, JAK3 has been demonstrated to be an important regulator of transport processes across the plasma membrane. Either directly or indirectly JAK3 affects the expression of transport proteins, including various ion channels, a number of cellular carriers and the Na+/K+ pump. More specifically, JAK3 is involved in the regulation of various potassium, sodium, and chloride ion channels, a wide variety of Na+-coupled cellular carriers including the high-affinity Na+ coupled glucose transporter SGLT1, the excitatory amino acid transporters EAAT1, EAAT2, EAAT3 and EAAT4, the peptide transporters PepT1 and PepT2, CreaT1 and theNa+/K+-ATPase. Via these transporters this kinase plays a role in various physiological and pathophysiological processes. Additional research is needed to investigate the effects of JAK3 on other cellular transporters and the underlying mechanisms.
Export Options
About this article
Cite this article as:
Sopjani Mentor*, Thaçi Shpëtim, Krasniqi Berat, Selmonaj Miranda, Rinnerthaler Mark and Dërmaku-Sopjani Miribane *, Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3, Current Medicinal Chemistry 2017; 24 (21) . https://dx.doi.org/10.2174/0929867324666170203122625
DOI https://dx.doi.org/10.2174/0929867324666170203122625 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Current Drug Targets Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations
Current Pharmaceutical Biotechnology Angiogenesis and Hemostasis in Hematological Neoplasias
Current Drug Targets Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Fungal Infection in Cystic Fibrosis
Current Respiratory Medicine Reviews Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Topical Therapy for Actinic Keratoses: Current and Evolving Therapies
Reviews on Recent Clinical Trials Small-Molecule Inhibitors Targeting eIF4A in Leukemia
Current Protein & Peptide Science HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents